Increased Selenoprotein P Levels in Subjects with Visceral Obesity and Nonalcoholic Fatty Liver Disease

Hae Yoon Choi¹, Soon Young Hwang², Chang Hee Lee³, Ho Cheol Hong¹, Sae Jeong Yang¹, Hye Jin Yoo¹, Ji A Seo¹, Sin Gon Kim¹, Nan Hee Kim¹, Sei Hyun Baik¹, Dong Seop Choi¹, Kyung Mook Choi¹

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, ²Department of Biostatistics, Korea University College of Medicine, ³Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

Background: Selenoprotein P (SeP) has recently been reported as a novel hepatokine that regulates insulin resistance and systemic energy metabolism in rodents and humans. We explored the associations among SeP, visceral obesity, and nonalcoholic fatty liver disease (NAFLD).

Methods: We examined serum SeP concentrations in subjects with increased visceral fat area (VFA) or liver fat accumulation measured with computed tomography. Our study subjects included 120 nondiabetic individuals selected from participants of the Korean Sarcopenic Obesity Study. In addition, we evaluated the relationship between SeP and cardiometabolic risk factors, including homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hsCRP), adiponectin values, and brachial-ankle pulse wave velocity (baPWV).

Results: Subjects with NAFLD showed increased levels of HOMA-IR, hsCRP, VFA, and several components of metabolic syndrome and decreased levels of adiponectin and high density lipoprotein cholesterol than those of controls. Serum SeP levels were positively correlated with VFA, hsCRP, and baPWV and negatively correlated with the liver attenuation index. Not only subjects with visceral obesity but also those with NAFLD exhibited significantly increased SeP levels (P<0.001). In multiple logistic regression analysis, the subjects in the highest SeP tertile showed a higher risk for NAFLD than those in the lowest SeP tertile, even after adjusting for potential confounding factors (odds ratio, 7.48; 95% confidence interval, 1.72 to 32.60; P=0.007).

Conclusion: Circulating SeP levels were increased in subjects with NAFLD as well as in those with visceral obesity and may be a novel biomarker for NAFLD.

Keywords: Hepatokine; Insulin resistance; Non-alcoholic fatty liver disease; Obesity; Selenoprotein P

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD), a disease spectrum that includes simple steatosis, nonalcoholic steatohepatitis (NASH) and cirrhosis, has been increasingly recognized as the hepatic manifestation of metabolic syndrome [1]. Visceral obesity is an essential component of metabolic syndrome and a risk factor for type 2 diabetes and cardiovascular diseases [2]. Furthermore, increased visceral fat induces systemic low-grade inflammation, contributing to the development of insulin resistance in humans and mice [3]. Both inflammation and insulin resistance are considered to be pivotal pathogenic mechanisms of NAFLD, as well as metabolic syndrome, type 2 diabetes, and atherosclerosis [4].

There is mounting evidence implicating adipokines secreted from adipose tissue in the pathogenesis and progression of NAFLD, in addition to the development of insulin resistance and inflammation [5]. In previous studies, including one by the current authors, decreased circulating adiponectin levels have been found in subjects with NAFLD and appear to be in-
versely related to hepatic insulin resistance, hepatic fat content, and degree of liver inflammation [6,7]. Furthermore, we recently found that retinol binding protein 4, a novel adipokine associated with insulin resistance, appears to be significantly associated with NAFLD [8]. Analogous to adipose tissue, it is hypothesized that the liver may regulate systemic energy metabolism through production of secretory proteins known as hepatokines. In fact, several previous studies have demonstrated that hepatokines, such as fetuin-A and fibroblast growth factor 21 (FGF21), are associated with NAFLD. Stefan et al. [9] showed that high fetuin-A levels are associated with insulin resistance in humans and are elevated in subjects with fat accumulation in the liver. Moreover, Dushay et al. [10] reported that FGF21 values correlate with body mass index (BMI) and may be a novel biomarker for NAFLD.

Selenoprotein P (SeP) is a secretory protein primarily produced and released by the liver [11]. Recently, Misu et al. [12] found that hepatic SeP mRNA expression was increased in subjects with type 2 diabetes. Furthermore, administration of SeP aggravated insulin resistance in both hepatocytes and myocytes. Conversely, both genetic deletion and RNA interference-mediated knockdown of SeP improved insulin sensitivity and glucose tolerance in mice. Therefore, they concluded that SeP may be a promising target for the treatment of insulin resistance-associated diseases [12]. In our recent study, we also found that circulating SeP concentrations were elevated according to glucose metabolism dysregulation and were related to various cardiometabolic parameters including insulin resistance, inflammation, and atherosclerosis [13]. On the other hand, Zhang and Chen [14] recently demonstrated that SeP has a major role in adipocyte differentiation through the regulation of oxidative stress and inflammatory response. Although previous studies have shown a close relationship among insulin resistance, inflammation, and NAFLD, as far as we know, there is no previous report evaluating the association between SeP and NAFLD.

In the present study, we examined serum SeP levels in subjects with increased visceral fat area (VFA) or liver fat accumulation measured with computed tomography (CT). Our study participants were nondiabetic Korean subjects selected from an ongoing prospective observational cohort study. Furthermore, we evaluated the relationship between SeP levels and cardiometabolic risk factors, including homeostasis model of insulin resistance (HOMA-IR) values, high sensitivity C-reactive protein (hsCRP) levels, adiponectin concentrations, and arterial stiffness measured with brachial-ankle pulse wave velocity (baPWV).

**METHODS**

**Subjects and data collection**

Study subjects were selected from the participants of the Korean Sarcopenic Obesity Study (KSOS), an ongoing epidemiologic study supported by the Korea Science and Engineering Foundation (KOSEF). This prospective observational cohort study was designed to examine the prevalence of sarcopenia and sarcopenic obesity in Korean adults with or without diabetes and to evaluate their effects on metabolic disorders and health outcomes; details have been previously published [15,16]. Participants were enrolled in the KSOS cohort between September 2007 and August 2009, and a follow-up survey was conducted thereafter. Study participants included 446 well-functioning, community-dwelling, healthy volunteers without diabetes recruited from residents of Seoul, Korea and 428 diabetic patients being treated at the Diabetes Center of Korea University Guro Hospital. No participants had a history of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization), stage 2 hypertension (resting blood pressure, $\geq 160/100$ mm Hg), malignancy, or severe renal or hepatic disease. Subjects taking medications that might affect body weight or body composition were excluded. For this study, we excluded diabetic subjects to eliminate possible confounding effects because a previous study reported increased SeP concentrations in diabetic subjects [12]. In addition, the following exclusion criteria were also used: alcohol consumption $>20$ g/day in men and $>10$ g/day in women, a positive test for hepatitis B surface antigen or hepatitis C antibody, and use of herbal medications within the previous 6 months. Among the nondiabetic subjects, 76 subjects had NAFLD by applying our definition. Finally, 60 subjects with NAFLD and 60 age- and sex-matched controls were selected from the nondiabetic KSOS participants using the baseline data for abdominal CT and other epidemiological characteristics. All participants provided written informed consent, and the Korea University Institutional Review Board, in accordance with the Declaration of Helsinki of the World Medical Association, approved the study protocol.

**Anthropometric and laboratory measurements**

We calculated BMI as weight/height$^2$ (kg/m$^2$), and waist cir-
cumference was measured at the midpoint between the lower border of the rib cage and iliac crest. All blood samples were obtained in the morning following an 8-hour overnight fast and were immediately stored at -70°C for subsequent assays. Serum triglyceride and high density lipoprotein cholesterol (HDL-C) levels were determined enzymatically using a chemistry analyzer (Hitachi 747; Hitachi, Tokyo, Japan). Low density lipoprotein cholesterol (LDL-C) concentrations were estimated using the Friedewald formula, and a glucose oxidase method was employed to measure plasma glucose levels. Levels of hsCRP and serum insulin were measured with two different electrochemiluminescence immunoassays (Daiichi Pure Chemicals Co., Tokyo, Japan; Roche Diagnostics, Basel, Switzerland). The homeostasis model assessment estimate of insulin resistance (HOMA-IR) was calculated from plasma insulin and glucose values. Serum adiponectin levels were measured with an enzyme linked immunosorbent assay (ELISA, Mesdia, Seoul, Korea), and the intra-assay and inter-assay coefficients of variation (CV) were 5.0% in both cases. Serum SeP levels were determined using a commercially available human ELISA kit (USCN Life Science, Wuhan, China) with an intra-assay CV of 6.7% and an inter-assay CV of 4.7%.

**CT**

Abdominal VFA and total abdominal fat area were measured via CT scan without an intravenous contrast agent (Brilliance 64; Philips Medical Systems, Cleveland, OH, USA). With the subject in the supine position, a 3-mm CT slice scan was acquired at the L4 to L5 level to measure visceral fat and total abdominal fat areas. The cross-sectional surface areas (in cm²) of different abdominal fat compartments were calculated from this slice using commercially available CT software (Rapidia 2.8; INFINITT, Seoul, Korea). We were able to determine adipose tissue area electronically by setting the attenuation values for a region of interest within the range of -190 to -30 Hounsfield units (HU). The VFA was quantified by measuring the intra-abdominal cavity at the internal aspect of the abdominal and oblique muscle walls surrounding the cavity and the posterior aspect of the vertebral body. Subcutaneous fat area (SCFA) was calculated by subtracting VFA from total fat area. Visceral obesity was defined as a VFA of more than 100 cm² [17].

**Definition of NAFLD**

NAFLD was diagnosed using an unenhanced CT, read by one experienced radiologist who was blinded to the anthropomet-
sure, triglyceride, HDL-C, adiponectin, hsCRP, and HOMA-IR levels. Data were analyzed using SPSS for Windows version 12.0 (SPSS Inc., Chicago, IL, USA) and SAS for Windows version 9.0 (SAS Institute Inc., Cary, NC, USA). A P value of less than 0.05 indicated statistical significance.

RESULTS

Clinical and laboratory characteristics of the participants

The clinical and metabolic characteristics of the participants are summarized in Table 1. Although age and sex distributions did not differ between groups, subjects with NAFLD had significantly higher BMI, waist circumference, systolic blood pressure, total cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, HOMA-IR, hsCRP, VFA, and SCFA values and lower HDL-C and adiponectin levels than those of the control group.

Clinical and laboratory parameters according to SeP tertile

Table 2 presents the clinical and laboratory variables stratified by SeP level tertile. BMI, waist circumference, systolic blood pressure, triglycerides, HOMA-IR, hsCRP, baPWV, VFA, and SCFA levels increased significantly with increasing SeP levels. Interestingly, subjects with NAFLD (P<0.001), as well as those with visceral obesity (P<0.001) exhibited increased SeP concentrations compared to the control group (Fig. 1).

Correlation between SeP level and cardiometabolic risk factors

Circulating SeP levels showed a significant positive correlation with VFA measured with abdominal CT (r=0.338, P<0.001) and a negative correlation with LAI (r=-0.333, P<0.001), which inversely reflects hepatic fat accumulation. Furthermore, SeP concentrations revealed a significant positive correlation with both hsCRP levels (r=0.749, P<0.001) and baPWV (r=0.262, P=0.004).

Multiple logistic regression analysis of the association between SeP and NAFLD

Multiple logistic regression analysis was performed using NAFLD as a dependent variable and SeP as an independent variable (Table 3). In the unadjusted model, subjects in the highest SeP tertile showed a higher risk of NAFLD compared to those in the lowest SeP tertile (OR, 10.55; 95% CI, 3.73 to 29.84; P<0.001). Furthermore, multivariate analysis revealed that the association between NAFLD and SeP levels remained significant even after adjusting for potential confounders such as age, sex, BMI, current smoking status, blood pressure, triglycerides, HDL-C, hsCRP, adiponectin, and HOMA-IR val-

### Table 1. Anthropometric and metabolic characteristics of study subjects

| Variable                  | Control (n=60) | NAFLD (n=60) | P value |
|---------------------------|---------------|--------------|---------|
| Age, yr                   | 47.0±13.0     | 49.1±13.1    | 0.374   |
| Sex, M/F                  | 29/31         | 30/30        | 0.855   |
| No. of tobacco smokers (%)| 27 (45.0)     | 20 (33.3)    | 0.289   |
| BMI, kg/m²                 | 24.0±3.2      | 26.8±2.9     | <0.001  |
| Waist circumference, cm   | 83.5±8.8      | 91.2±6.9     | <0.001  |
| SBP, mm Hg                | 119.5±11.9    | 124.6±13.0   | 0.028   |
| DBP, mm Hg                | 78.8±9.3      | 81.8±10.8    | 0.109   |
| Total cholesterol, mg/dL  | 181.7±29.5    | 198.3±39.7   | 0.011   |
| LDL-C, mg/dL              | 103.3±24.3    | 112.1±34.4   | 0.109   |
| HDL-C, mg/dL              | 55.3±14.6     | 48.3±12.3    | 0.005   |
| Triglyceride, mg/dL       | 95.5          | 143.0        | <0.001  |
| AST, IU/L                 | 19.0          | 24.0         | <0.001  |
| ALT, IU/L                 | 17.5          | 24.0         | <0.001  |
| FPG, mg/dL                | 97.9±16.0     | 99.0±15.4    | 0.706   |
| HOMA-IR                   | 1.63          | 2.78         | <0.001  |
| Selenoprotein P, ng/mL    | 530.4 (246.2-1478.2) | 1,509.3 (899.0-2773.2) | <0.001 |
| Adiponectin, µg/mL        | 0.33          | 0.76         | 0.013   |
| baPWV, µg/mL              | 5.66          | 3.37         | <0.001  |
| Visceral fat area, cm²    | 105.6±53.9    | 153.7±55.9   | <0.001  |
| Subcutaneous fat area, cm²| 155.8±69.3    | 206.9±75.7   | <0.001  |

Values are presented as mean±standard deviation, median (interquartile range), or number (%). P values were calculated using an independent two-sample t-test or the Mann–Whitney U test.

NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high sensitivity C-reactive protein; baPWV, brachial-ankle pulse wave velocity.

Diabetes Metab J 2013;37:63-71 http://e-dmj.org
Selenoprotein P and NAFLD

Discussion

The present study demonstrates that circulating SeP concentrations appear to be significantly increased in subjects with visceral obesity. In addition, SeP levels appear to be significantly correlated with cardiometabolic risk factors, such as waist circumference, VFA, HOMA-IR, hsCRP, and baPWV values of arterial stiffness. Furthermore, subjects in the highest SeP tertile showed a 7.5 times greater risk of NAFLD than those in the lowest SeP tertile, even after adjustments for age, sex, BMI, and other confounding factors.

NAFLD is now the leading cause of liver disease in developed countries, with an estimated prevalence of 20% to 35% in the general population [22]. NAFLD is a strong predictor of NASH and also predicts liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma [23]. The development of NAFLD is closely related to visceral obesity, insulin resistance, and other components of metabolic syndrome [22]. Pathogenesis of NAFLD was traditionally explained using the “two-hit theory,” [24] whereby the primary insult was accompanied by fat accumulation in hepatocytes and increased oxidative stress. These occurrences lead to inflammation, which induces the second “hit” in the progression to NASH or liver cirrhosis [24].

Table 2. Clinical variables stratified by selenoprotein P tertile

| Variable                     | 1st tertile (n=40)       | 2nd tertile (n=39)       | 3rd tertile (n=40)       | P value |
|------------------------------|--------------------------|--------------------------|--------------------------|---------|
| Selenoprotein P, ng/mL       | 307 (138-394)           | 1,068 (829-1,409)       | 2,948 (1,966-4,359)     | <0.001  |
| Age, yr                      | 44.7±13.2               | 52.1±11.0                | 47.1±14.0                | 0.034   |
| Sex, M/F                     | 18/21                   | 21/18                    | 20/20                    | 0.733   |
| No. of tobacco smokers, %    | 14 (35)                 | 19 (49)                  | 14 (35)                  | 0.449   |
| BMI, kg/m²                   | 23.6±3.1                | 25.2±2.7                 | 27.3±3.3                 | <0.001  |
| Waist circumference, cm      | 82.8±8.6                | 86.7±7.0                 | 92.2±8.2                 | <0.001  |
| SBP, mm Hg                   | 117.6±13.0              | 123.7±10.2               | 124.5±13.5               | 0.027   |
| DBP, mm Hg                   | 77.8±9.9                | 80.7±8.9                 | 82.1±11.3                | 0.155   |
| Total cholesterol, mg/dL     | 185.8±36.2              | 183.5±30.4               | 199.9±39.1               | 0.088   |
| LDL-C, mg/dL                 | 106.9±30.2              | 100.3±27.8               | 115.9±30.8               | 0.069   |
| HDL-C, mg/dL                 | 55.5±15.1               | 49.8±13.4                | 49.5±12.3                | 0.090   |
| Triglyceride, mg/dL          | 94.0 (70.0-135.3)       | 138.0 (89.0-244.0)       | 134.5 (93.3-192.5)       | 0.010   |
| AST, IU/L                    | 19.5 (16.0-24.0)        | 20.0 (17.0-28.0)         | 20.0 (16.0-26.8)         | 0.445   |
| ALT, IU/L                    | 17.0 (14.0-22.0)        | 21.0 (17.0-29.0)         | 22.0 (16.3-31.8)         | 0.036   |
| FPG, mg/dL                   | 95.3±14.3               | 101.9±19.1               | 98.7±12.7                | 0.174   |
| HOMA-IR                      | 1.60 (1.19-2.36)        | 2.47 (1.58-3.54)         | 2.71 (1.81-3.70)         | 0.002   |
| hsCRP, mg/L                  | 0.17 (0.11-0.27)        | 0.62 (0.41-0.74)         | 1.84 (1.25-3.67)         | <0.001  |
| Adiponectin, µg/mL           | 5.50 (3.22-7.84)        | 3.42 (2.46-5.14)         | 3.84 (2.55-6.53)         | 0.055   |
| baPWV, cm/sec                | 1258.8±204.4            | 1,326.4±217.7            | 1,389.4±229.4            | 0.030   |
| Visceral fat area, cm²       | 103.9±59.8              | 131.5±57.3               | 157.7±58.2               | <0.001  |
| Subcutaneous fat area, cm²   | 156.0±60.1              | 170.3±74.9               | 222.1±88.6               | <0.001  |

Values are presented as mean±standard deviation, median (interquartile range), or number (%). P values represent overall differences across groups as determined by (nonparametric) ANOVA for continuous variables and Fisher's exact test or Pearson's chi-squared test for categorical variables.

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high sensitivity C-reactive protein; baPWV, brachial-ankle pulse wave velocity.

Same letters indicate no statistical significance based on Tukey’s HSD post-hoc test and the Bonferroni correction.

Ues (OR, 7.48; 95% CI, 1.72 to 32.60, highest vs. lowest SeP tertile; P=0.007).

http://e-dmj.org Diabetes Metab J 2013;37:63-71
Recent studies have revealed the role of hepatokines, novel factors secreted from the liver under excess fat accumulation, that are involved in the regulation of systemic energy metabolism [23]. Fat accumulation in the liver induces the production of the glycoprotein fetuin-A, which aggravates insulin resistance, represses adiponectin production, and induces subclinical inflammation [9,25]. Furthermore, Stefan et al. [9] reported that plasma fetuin-A levels are elevated in subjects with fat accumulation in the liver. Reinehr and Roth [26] also observed that fetuin-A levels were higher in children with NAFLD and were related to insulin resistance and to features of metabolic syndrome. On the other hand, FGF21 is a hepatic protein that plays a critical role in systemic metabolism, and circulating FGF21 levels are increased in subjects with obesity, diabetes, or metabolic syndrome [27]. Yilmaz et al. [28] reported that serum FGF21 levels are increased in subjects with NAFLD regardless of potential confounders.

Misu et al. [12] recently reported that hepatic SeP mRNA expression was significantly upregulated in subjects with type 2 diabetes according to serial analysis of gene expression and DNA chip methods. Treatment with SeP impaired insulin signaling in hepatocytes and myocytes both in vitro and in vivo. Moreover, knockdown of SeP in the liver or SeP-deficient mice led to improved glucose tolerance and insulin resistance. As a mechanism, they found that the metabolic actions of SeP were mediated by inactivation of adenosine monophosphate-activated protein kinase. Therefore, they concluded that the liver-derived secretory protein SeP may be a target for the treatment

Table 3. Multiple logistic regression analysis with nonalcoholic fatty liver disease as a dependent variable and selenoprotein P as an independent variable

| Model          | Unadjusted | Model 1 | Model 2 | Model 3 | Model 4 |
|----------------|------------|---------|---------|---------|---------|
| T1             | 1.00       | 1.00    | 1.00    | 1.00    | 1.00    |
| T2 (OR, 95% CI)| 5.75 (2.11-15.69) | 5.56 (1.98-15.57) | 5.54 (1.76-16.76) | 4.78 (1.42-16.10) | 6.30 (1.51-26.28) |
| P value        | 0.001      | 0.001   | 0.003   | 0.011   | 0.012   |
| T3 (OR, 95% CI)| 10.55 (3.73-29.84) | 10.48 (3.69-29.75) | 5.68 (1.78-18.10) | 5.23 (1.52-18.03) | 7.48 (1.72-32.60) |
| P value        | <0.001     | <0.001  | 0.003   | 0.009   | 0.007   |

Model 1: adjusted for age, sex; Model 2: adjusted for age, sex, body mass index (BMI), and smoking status; Model 3: adjusted for age, sex, BMI, smoking status, systolic blood pressure (SBP), diastolic blood pressure (DBP), triglycerides, and high density lipoprotein cholesterol (HDL-C) values; Model 4: adjusted for age, sex, BMI, smoking status, SBP, DBP, triglycerides, HDL-C, high sensitivity C-reactive protein, adiponectin, and homeostasis model assessment of insulin resistance values.

OR, odds ratio; CI, confidence interval.
of insulin-resistance-associated diseases, including type 2 diabetes [12]. In this study, we found for the first time that novel hepatokine SeP concentrations were significantly correlated with LAI and were increased in subjects with NAFLD regardless of potential confounding factors. LAI is an objective parameter that has a very close quantitative correlation with histologic steatosis [19]. In our previous study, LAI showed a correlation with various anthropometric and metabolic parameters associated with metabolic syndrome [20].

Recent studies using proton magnetic resonance spectroscopy have shown that hepatic lipid content is directly correlated with visceral fat [29]. In this study, SeP concentration was significantly associated with VFA, and subjects with visceral obesity showed increased circulating SeP levels compared to controls. The strong correlation of VFA with liver fat may be attributable to dysregulated adipokine production via a reduced production of adiponectin and increased productions of tumor necrosis factor-α and interleukin-6 [23]. In the present study, adiponectin concentrations were significantly decreased in subjects with NAFLD compared to the levels in the controls, a finding that is compatible with previous studies. However, the correlation between circulating adiponectin and SeP levels was not significant in our study subjects (r = -0.226, P = 0.085). Further studies may be needed to elucidate the relationship and interactions between SeP and adiponectin.

Recently, NAFLD has emerged as an independent risk factor for cardiovascular disease. Several studies have reported increased carotid intima-media thickness and carotid plaque in subjects with NAFLD [30]. The present study demonstrated that circulating SeP levels appear to be significantly associated with arterial stiffness, as well as hepatic fat accumulation, in subjects without cardiovascular disease. Arterial stiffness measured with baPWV is a useful marker for the assessment of increased cardiovascular disease risk. Many previous studies have reported that arterial stiffness appears to be an independent risk factor for cardiovascular disease and subsequent mortality [31]. Previously, we observed that baPWV is closely associated with inflammatory markers as well as cardiometabolic risk factors of metabolic syndrome [32,33]. Moreover, the present study showed a close correlation between SeP and hsCRP levels (r = 0.749, P < 0.001), which has emerged as the most powerful inflammatory marker of future cardiovascular risk [34]. Considering the close relationship between SeP and cardiovascular risk factors, such as inflammation, type 2 diabetes and visceral obesity, these results may support the role of SeP in the linkage between NAFLD and atherosclerosis.

Our study has several limitations to be considered. First, it was performed using baseline data from an ongoing prospective cohort study; therefore, it is not possible to define causality. We are planning to perform a follow-up survey to explore the longitudinal effects of SeP on NAFLD in Korean adults. Also, the number of study participants was relatively small. Another limitation of our study was that we did not perform liver biopsies for the diagnosis of NAFLD. Although liver biopsy is regarded as a gold standard for the diagnosis of NAFLD, it is invasive and associated with morbidities and rare cases of mortality [22]. Furthermore, as histological lesions of NASH are not evenly distributed in the liver, the inherent sampling error of liver biopsies may result in substantial misdiagnosis and staging inaccuracies [35].

The present study also has several advantages. Using predefined inclusion and exclusion criteria, we enrolled age- and sex-matched individuals from the subjects of a prudently designed cohort study. Also, we used abdominal CT, which is known as the most accurate method for measuring visceral fat. In addition, a diagnosis of NAFLD was defined based on an objective method of averaging LAI in multiple points of liver parenchyma [19].

In conclusion, the present study demonstrated that novel hepatokine SeP concentrations were increased in subjects with visceral obesity. In addition, circulating SeP levels appear to be significantly associated with cardiovascular risk factors, including subclinical inflammation and arterial stiffness. Furthermore, SeP concentrations were shown to be significantly correlated with LAI and independently associated with NAFLD, even after adjusting for potential confounding factors. These results may warrant further investigation of this novel hepatokine in insulin resistance-related disorders, including metabolic liver diseases.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

Dr. Kyung Mook Choi was supported by the Mid-Career Researcher Program through an NRF grant funded by the Ministry of Education, Science, and Technology, Republic of Korea.
REFERENCES

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-31.

2. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000;23:465-71.

3. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-61.

4. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007;47:142-56.

5. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957-69.

6. Vanni E, Bugianesi E, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007;47:142-56.

7. Kim SG, Kim HY, Seo JA, Lee KW, Oh JH, Kim NH, Choi KM, Baik SH, Choi DS. Relationship between serum adiponectin concentration, pulse wave velocity and nonalcoholic fatty liver disease. Eur J Endocrinol 2005;152:225-31.

8. Seo JA, Kim NH, Park SY, Kim HY, Ryu OH, Lee KW, Lee J, Kim DL, Choi KM, Baik SH, Choi DS, Kim SG. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) 2010;68:555-60.

9. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006;29:853-7.

10. Burk RF, Hill KE. Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annu Rev Nutr 2005;25:215-35.

11. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, Ishikura K, Ando H, Takeshita Y, Ota T, Sakurai M, Yamashita T, Mizukoshi E, Honda M, Miyamoto K, Kubota T, Kubota N, Kadowaki T, Kim HJ, Lee IK, Minokoshi Y, Saito Y, Takahashi K, Yamada Y, Takakura N, Kaneko S. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 2010;12:483-95.

12. Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab 2011;96:E1325-9.

13. Zhang Y, Chen X. Reducing selenoprotein P expression suppresses adipocyte differentiation as a result of increased preadipocyte inflammation. Am J Physiol Endocrinol Metab 2011;300:E77-85.

14. Kim TN, Yang SJ, Yoo HJ, Lim KI, Kang HJ, Song W, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. Int J Obes (Lond) 2009;33:885-92.

15. Kim TN, Park MS, Yang SJ, Yoo HJ, Kang HJ, Song W, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care 2010;33:1497-9.

16. Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J 2002;66:987-92.

17. Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006;49:540-52.

18. Limandon P, Raman SS, Lassman C, Sayre J, Ghoberial RM, Busuttil RW, Saab S, Lu DS. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 2004;230:276-80.

19. Yoo HJ, Park MS, Lee CH, Yang SJ, Kim TN, Lim KI, Kang HJ, Song W, Yeon JE, Baik SH, Choi DS, Choi KM. Cutoff points of abdominal obesity indices in screening for non-alcoholic fatty liver disease in Asians. Liver Int 2010;30:1189-96.

20. Burk RF, Hill KE. Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annu Rev Nutr 2005;25:215-35.
23. Kantartzis K, Schick F, Haring HU, Stefan N. Environmental and genetic determinants of fatty liver in humans. Dig Dis 2010; 28:169-78.
24. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-5.
25. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 2008;3: e1765.
26. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 2008;93:4479-85.
27. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57: 1246-53.
28. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010;40:887-92.
29. Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009;49:791-801.
30. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792-8.
31. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:932-43.
32. Choi KM, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH. Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome. Diabetes Res Clin Pract 2004;66:57-61.
33. Choi KM, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 2009;132:96-101.
34. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-71.
35. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Pynnard T; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.